FY2026 EPS Estimates for OR Royalties Raised by Scotiabank

OR Royalties Inc. (NYSE:ORFree Report) – Scotiabank boosted their FY2026 earnings per share estimates for OR Royalties in a report issued on Wednesday, August 19th. Scotiabank analyst T. Jakusconek now forecasts that the basic materials company will post earnings of $1.26 per share for the year, up from their prior forecast of $1.24. Scotiabank currently has a “Sector Perform” rating and a $42.00 price target on the stock. The consensus estimate for OR Royalties’ current full-year earnings is $1.25 per share.

Other analysts have also recently issued research reports about the stock. Zacks Research cut shares of OR Royalties from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Weiss Ratings lowered shares of OR Royalties from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, July 24th. Jefferies Financial Group dropped their target price on shares of OR Royalties from $40.00 to $34.00 and set a “hold” rating for the company in a report on Monday, July 6th. Royal Bank Of Canada reduced their price target on shares of OR Royalties from $50.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday, July 9th. Finally, Wall Street Zen lowered OR Royalties from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $40.50.

Get Our Latest Stock Analysis on OR

OR Royalties Price Performance

Shares of NYSE OR opened at $38.93 on Monday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.28 and a current ratio of 2.28. OR Royalties has a one year low of $27.54 and a one year high of $48.06. The firm has a market capitalization of $7.26 billion, a P/E ratio of 25.96 and a beta of 0.75. The company’s fifty day moving average is $31.70 and its two-hundred day moving average is $36.49.

OR Royalties (NYSE:ORGet Free Report) last released its quarterly earnings data on Wednesday, August 5th. The basic materials company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.01. OR Royalties had a return on equity of 16.41% and a net margin of 78.04%.The firm had revenue of $97.82 million during the quarter, compared to analysts’ expectations of $97.93 million.

Institutional Investors Weigh In On OR Royalties

A number of large investors have recently added to or reduced their stakes in the business. State of Wyoming purchased a new position in OR Royalties during the 1st quarter valued at about $28,000. FIL Ltd purchased a new stake in shares of OR Royalties in the fourth quarter valued at about $29,000. Banque Cantonale Vaudoise purchased a new stake in shares of OR Royalties in the first quarter valued at about $37,000. Grove Bank & Trust acquired a new stake in shares of OR Royalties in the second quarter valued at approximately $32,000. Finally, Assetmark Inc. acquired a new stake in shares of OR Royalties in the fourth quarter valued at approximately $36,000. 68.52% of the stock is owned by institutional investors and hedge funds.

OR Royalties Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.065 per share. This represents a $0.26 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. OR Royalties’s payout ratio is 16.67%.

OR Royalties Company Profile

(Get Free Report)

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.

Recommended Stories

Earnings History and Estimates for OR Royalties (NYSE:OR)

Receive News & Ratings for OR Royalties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OR Royalties and related companies with MarketBeat.com's FREE daily email newsletter.